105 results about "Joints inflammation" patented technology

A device is provided, in direct skin contact, surrounding an injured area for the treatment, reduction of joint inflammation, edema and excitation of neural and muscular stimulation associated with human and mammal tissues. This therapeutic light source includes a multiplicity of light emitting diodes (LED's) found in the ranges of 350 nm to 1000+ nm and fiber optic connections. A neoprene type material or other non-allergenic material is used to set the LED's and fiber optics in layers consisting of contact with the skin to few centimeters from the skin tissue. Distance will vary from contact or near contact with devices to several millimeters of separation. Each LED array is independently controlled allowing for optimal modulation of light frequencies and wavelengths. Technology is integrated allowing for biomedical feedback of tissue temperature and other statistical information. A low voltage, portable power supply, is integrated into the device as well as an analog / digital, input / output connection device. The design will be created for continuous wear, flexibility and comfort.

The instant invention provides a method of treating or preventing osteoarthritis, joint effusion, joint inflammation and pain, synovitis, lameness, post operative arthroscopic surgery, deterioration of proper joint function including joint mobility, the reduction or inhibition of metabolic activity of chondrocytes, the activity of enzymes that degrade cartilage, the reduction or inhibition of the production of Hyaluronic acid, said method comprising orally administering to a mammalian species a therapeutically effective amount of Hyaluronic Acid or pharmaceutically acceptable salts thereof. Additionally, compositions containing hyaluronic acid; chondroitin sulfate, and glucosamine sulfate in a paste formulation are also disclosed which can be administered on their own or can be used as a feed additive.

The invention provides the use of a glucocorticoid substance which has a minimal systemic effect in the manufacture of a medicament for oral or rectal administration for non-topical use in the treatment of joint inflammation.

This invention provides methods and formulations for treating an inflammatory disease or reducing an inflammatory reaction comprising administering a fortified formulation comprising stabilized rice bran derivative and a fortification agent. Preferred rice bran derivatives are rice bran oil and the solubilized fraction of rice bran. Preferred fortification agents are glucosamine derivative, methylsulfonylmethane, yucca concentrate, and grape seed extract.

The present invention provides a composition, and a method of use thereof for treating connective tissue damage in man and in animals, which comprises a therapeutically effective amount of chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan (hyaluronic acid). Particularly, the present invention provides a composition, and a method of use thereof, for treating connective tissue damage including, but not limited to, arthritic disease, osteoarthritis, rheumatoid arthritis, osterochondrosis dessicans, cartilage damage, joint injury, joint inflammation, joint synovitis, degenerative joint disease (DJD), post surgical DJD, traumatic injury, fracture, tendon damage, ligament damage, skeletal damage, musculoskeletal damage, fiber damage, adipose tissue damage, blood cell damage, and plasma damage. Compositions for delivery of the present invention include those for parenteral, oral, and transmucosal delivery and for direct surgical placement onto the affected tissues.

The invention provides food for caring pet jonit, which is prepared with the following raw materials in parts by weight: 100 parts of lean meat, 1.0-2.0 part(s) of glycerin, 0.5-0.8 part of shrimp shell meal, 0.1-0.5 part of rosemary, 0.1-0.5 part yucca, 0.01-0.05 part of mineral, 0.1-0.5 part of vitamin E, 0.1-0.5 part of vitamin C, 0.1-0.5 part of glucosamine, 0.3-1.0 part of taurine and 0.1-0.5 part of chondroitin sulfate. Due to the addition of the components such as the shrimp shell meal, the chondroitin sulfate, the glucosamine and the like which can protect the joint and eliminate the joint inflammation, the pet food provided by the invention can protect the joint of the pet cat / dog, relieve the joint pain, and ease the joint inflammation.

The use of compounds that block complement component C5 or its active fragments C5a and / or C5b (such compounds collectively referred to as “C5 blockers”) to treat established joint inflammation (arthritis) is disclosed. Administration of such C5 blockers has been found to: 1) arrest and / or reduce inflammation in joints which are already inflamed, and 2) inhibit the spread of inflammation to unaffected joints.

Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof:are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of asthma, COPD, ARDS, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.

The invention relates to a composition for increasing the bone mineral density and preparation and a preparation method thereof. The composition is mainly prepared from, by weight of parts, calcium carbonate, D-glucosamine hydrochloride, chondroitin sulfate, collagen protein, a casein phosphopepetides, a davallia mariesii extract and a vitamin K2. On the specific matched condition, the effect of remarkable synergistic interaction for treating osteoporosis is achieved, and the effects of blocking calcium loss and reinforcing calcium absorption are achieved; after traditional Chinese medicines of shaddock peels, chicken shells, purple bergenia herb and schisandra chinensis are added, the effect of increasing the bone density is further enhanced, and meanwhile the effects of treating the joint inflammation, tonifying the spleen and the kidney, strengthening tendons and bones, improving immunity and the like are achieved.

A method is provided comprising steps for (a) dispensing a topical product having a set of ingredients, wherein the set of ingredients provides pain relief to an affected area of a user; and (b) delivering the topical product via a sonic device to the affected area of a user, wherein the affected area includes joint inflammation, wherein the sonic device comprises an elongated body having an massager head receiving area designed to receive a massager head, the combination of the sonic device and the attached massager head producing a vibrating massager promoting optimal absorption of the set of ingredients designed to stimulate and increase blood flow to the joint inflammation providing a reduction of pain for the user, wherein the sonic device and topical product are packaged together in a single packaging unit.

The invention discloses a preparation method of functional food having the effects of nourishing cartilaginous tissues and resisting joint inflammation. The functional food comprises the following raw materials in percentage by weight: 3 to 40 percent of manggis extract, 5 to 30 percent of marasmius androsaceus extract, 5 to 40 percent of D-glucosamine hydrochloride, 0.1 to 10 percent of chondroitin sulfate and 1 to 15 percent of collagen. The preparation method comprises methods for controlling proportional content of the raw material components, extracting active ingredients of two raw materials and preparing a preparation. The functional food preparation has the effects of effectively nourishing the cartilaginous tissues of human bodies, diminishing inflammation and relieving pain.

The invention discloses a composition for promoting uric acid metabolism, improving gout and protecting joints, which is prepared from the following raw materials in parts by weight: 1-2 parts of marine fish oligopeptide, 2-3 parts of an olive fruit extract, 25-35 parts of a celery seed extract, 8-12 parts of a sour cherry extract and 0.3-0.7 part of a turmeric extract. The composition for promoting uric acid metabolism, improving gout and protecting joints has better uric acid reduction effect through the synergistic effect of each raw material, the reduction effect is obvious, the treatmenteffect is obvious and treatment time is short, through the mixing of raw materials, the effect is better than that of singly using one medicament or a plurality of medicaments, the synergistic effectis achieved, gout and joint inflammation caused by gout are effectively treated, the life quality of a patient is improved, and no side effect is caused; the preparation method of the composition is simple and can be produced on a large scale.

The invention relates to a composition for preventing and treating joint soft tissue injury and complications thereof. A complex formulation, which comprises bone collagen, sodium hyaluronate, mangosteen extract, pomegranate extract and vitamin C in specific proportions, is prepared. The composition has an anti-inflammatory effect, since the generation of PGE2 is reduced by lowering the activity of COX2. Meanwhile, the composition accelerates the restoration and generation of cartilage tissue and joint fluid and lowers the degree of joint inflammation.

A herbal topical composition is used having complexed trace minerals capable of effectively reducing bone and joint inflammation by inhibiting inflammation pathways and in particular COX-2. The herbal composition having trace elements in a topical carrier reduces inflammation while avoiding the side effects associated with traditional drug therapy.

The present invention concerns amide derivatives of hyaluronic acid (HA) and biomaterials made of amide derivatives of hyaluronic acid (HA), particularly the hexadecylamide of HA, administered by the intraarticular route as a partial / total substitute for synovial fluid to treat joints affected by o steoarthrosis (OA) as well as cases of joint inflammation and / or trauma that cause damage to the cartilage and / or synovia (associated with pain). Lastly, we describe and claim their use in the treatment of joints where the entire structure shows signs of wear due to physiological aging.

The present invention provides a composition, and a method of use thereof for treating connective tissue damage in man and in animals, which comprises a therapeutically effective amount of chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan (hyaluronic acid). Particularly, the present invention provides a composition, and a method of use thereof, for treating connective tissue damage including, but not limited to, arthritic disease, osteoarthritis, rheumatoid arthritis, osterochondrosis dessicans, cartilage damage, joint injury, joint inflammation, joint synovitis, degenerative joint disease (DJD), post surgical DJD, traumatic injury, fracture, tendon damage, ligament damage, skeletal damage, musculoskeletal damage, fiber damage, adipose tissue damage, blood cell damage, and plasma damage. Compositions for delivery of the present invention include those for parenteral, oral, and transmucosal delivery and for direct surgical placement onto the affected tissues.

In a magnetic resonance method and apparatus for generating an analysis of an inflammation of a joint, for determining a proteoglycan proportion of a joint, and for generating an analysis of osteoarthritis of a joint, for a predetermined region within a body of a patient, a three-dimensional MR image data set is generated with a magnetic resonance imaging scanner. At least, a portion of a joint is located within the region. For each of several different automatically determined layers, a two-dimensional MR image is calculated from the three-dimensional MR image data set. For each layer, the thickness of a predetermined tissue, which is represented in the two-dimensional MR image corresponding to the layer, is determined, by means of which an analysis of a joint inflammation is automatically determined depending on the respective thicknesses. A further layer in the region is also automatically determined and, after injecting a contrast medium, a two-dimensional T1-weighted MR image is generated for this layer, from which a proteoglycan proportion is automatically determined. From the analysis of the joint inflammation and the proteoglycan proportion, it is then possible to perform a reproducible analysis of osteoarthritis of the joint.

The invention discloses an MRI hip joint inflammation segmentation and classification automatic quantitative grading sequential method, solves the problem that hip joint inflammation areas are difficult to quantify and grade due to uneven distribution of shapes, sizes and voxel values of hip joints, and realizes automatic accurate quantification and grading evaluation of the hip joint inflammationareas. According to the method, the hip joint inflammation area label value is modified in an inverse exponential proportion according to the voxel value, so that the problem of poor segmentation result caused by large voxel value difference of the hip joint inflammation area is solved; according to the method, a multi-scale convolution module GMS is designed to improve the segmentation effect ofhip joint inflammation regions with large shape and size differences; aiming at the problem that hip joint inflammation regions with small proportions are difficult to classify, a segmentation modeland a classification model are fused to improve the classification precision. According to the method, integrated automatic quantitative grading of hip joint inflammatory regions with multiple scalesand large voxel value differences is realized, and the quantitative grading efficiency is improved. The method can be used for quantitative and graded automatic treatment of the MRI hip joint inflammation area.

The instant invention provides a method and composition for treating or preventing osteoarthritis, joint effusion, joint inflammation and pain, synovitis, lameness, post operative arthroscopic surgery, deterioration of proper joint function including joint mobility, the reduction or inhibition of metabolic activity of chondrocytes, the activity of enzymes that degrade cartilage, said method comprising administering effective amounts of Boswellia Serrata, effective amounts of freeze dried green lipped mussle, effective amounts of white willow bark extract containing salicin, effective amounts of angelica root, effective amounts of glucosamine and salts thereof, effective amounts of chondroitin and salts thereof and effective amounts of omega 3 fatty acids.

The invention discloses a traditional Chinese medicine for treating rheumatic lumbocrural pain, comprising the following bulk drugs in parts by weight: 400 parts of rehmannia glutinosa, 200 parts of Chinese yam, 150 parts of poria cocos, 200 parts of common macrocarpium fruit, 150 parts of tree peony bark, 150 parts of oriental waterplantain rhizome, 50 parts of cinnamon, 50 parts of monkshood, 100 parts of cortex eucommiae, 100 parts of radix achyranthis bidentatae, 100 parts of astragalus membranaceus, 20 parts of ephedra root, 50 parts of male silk moth, a couple of geckoes, 350 parts of pizzle, 600 parts of canine kidney, 50 parts of cornu cervi pantotrichum, 50 parts of palmleaf raspberry fruit, 20 parts of cinnabar, 100 parts of cynomorium songaricum, 50 parts of tuner onion seed, 50 parts of fossil fragments, 50 parts of oyster shell, 50 parts of pericarpium citri reticulatae, 100 parts of medicinal Indian mulberry, 100 parts of actinolite, 100 parts of epimedium, 50 parts of leech and the like. The medicine can dispel wind and eliminate dampness, reinforce kidney to strengthen yang, clear liver and improve vision, improve blood circulation, diminish inflammation and relieve pain and has obvious efficacies of treating diseases such as limb weakness and night sweat caused by lumbocrural pain, kidney coldness, waist pain and joint inflammation; the medicine is short in course of treatment and rapid in healing, and has no toxic and side effects; and by using the medicine, the diseases can be thoroughly and radically treated, and can not be relapsed.

The invention discloses an siRNA (small interfering ribonucleic acid) composition inhibiting an ADAMTS-5 (a disintegrin-like and metalloproteinase with thrombospondin type 1motifs-5) gene and an ADAM17 (a disintegrin-like and metalloproteinase with thrombospondin type 1motifs 17) gene and an application of the siRNA composition. The invention discloses the chemically modified double-chain siRNA molecular composition which comprises at least one of double-chain siRNA molecules as shown as (1) and at least one double-chain siRNA molecules as shown as (2). The siRNA composition can serve as a treatment medicine of arthritis and relevant inflammation, and the siRNA composition and a preparation of the siRNA composition can be injected locally through a bone articular cavity to inhibit inflammatory factor expression to achieve treatment of the joint inflammation.

The invention discloses siRNA for inhibiting a gene ADAMTS-5 and application of the siRNA. The invention discloses a chemically modified double-chain siRNA molecule which is formed in the way that any chemical modification from (1) to (13) in the Specification is performed on at least one of the chains in the siRNA molecule in A (in the Specification), and the complementation is performed. The siRNA disclosed by the invention can be used as a medicine for treating arthritis and related inflammations, and the siRNA and a preparation thereof can be injected into local parts of bone joint cavities to inhibit the expression of inflammatory factors and further realize treatment of joint inflammation.

This invention relates to a compound which is [c]-fused bicyclic proline derivative, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising the compound or the salt thereof, and methods of treating diseases, including, but not limited to, methods of preventing or inhibiting joint cartilage damage and preventing or treating diseases characterized by joint cartilage damage, joint inflammation, or joint pain. The [c]-fused bicyclic proline derivatives are compounds of Formula I as described above. Diseases characterized by joint cartilage damage or joint pain include, for example, osteoarthritis and rheumatoid arthritis. Rheumatoid arthritis is also characterized by joint inflammation. This invention also relates to methods of synthesizing and preparing the [c]-fused bicyclic proline derivatives, or a pharmaceutically acceptable salt thereof.